HOUSTON, Sept. 16, 2025 – Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company specializing in regulatory T cell (Treg) biology, today reported encouraging preclinical data for COYA 303, its proprietary subcutaneous biologic combination of low-dose interleukin-2 (LD-IL-2) and GLP-1 receptor agonist (GLP-1RA). The results demonstrated broad systemic and central nervous system (CNS) anti-inflammatory effects in an animal model of inflammation, reinforcing the potential of COYA 303 as a novel treatment for neurodegenerative conditions such as Alzheimer’s disease.
Science Significance
The findings from the first animal cohort in a validated lipopolysaccharide (LPS)-induced systemic and neuroinflammation model showed that COYA 303 significantly reduced pro-inflammatory myeloid cells, increased anti-inflammatory immune subsets, and attenuated neuroinflammation in both the cortex and hippocampus. These effects aligned with earlier in vitro data showing enhanced Treg suppressive function in highly inflammatory environments.
COYA 303 demonstrated significant attenuation of neuroinflammation in critical brain regions and robust systemic immunomodulatory activity, suggesting that it may target the pathological drivers of neurodegeneration more effectively than conventional therapies.
Regulatory Significance
The company noted that Cohorts 2 and 3 of the study are underway, designed to test timing of treatment initiation relative to the onset of inflammation. Coya intends to share the full dataset through a peer-reviewed publication or scientific conference. Importantly, Coya highlighted that these findings support its development pathway for Alzheimer’s disease and related disorders, positioning COYA 303 within a broader regulatory context at a time of heightened interest in GLP-1RAs and Treg-enhancing biologics.
Advertisement
Business Significance
The positive preclinical results strengthen Coya’s pipeline and investor outlook. With COYA 303 showing potential synergies between LD-IL-2 and GLP-1RA, Coya can differentiate itself within the competitive neurodegeneration space. The findings also add strategic value as the company advances multiple platforms including Treg-derived exosomes and autologous Treg cell therapy. By validating systemic and CNS efficacy in a widely accepted model, Coya is laying groundwork for discussions with regulators and potential future partnerships.
Patients’ Significance
For patients with Alzheimer’s disease and other neurodegenerative conditions, chronic neuroinflammation is a key driver of disease progression and cognitive decline. Current treatment options provide limited relief, and there is a growing need for therapies that target underlying inflammatory mechanisms.
Coya’s COYA 303 may provide a dual-pronged benefit: boosting Treg function while dampening harmful myeloid activity, potentially slowing disease progression and improving quality of life for patients and their families.
Policy Significance
The development of therapies such as COYA 303 aligns with broader health policy objectives to address the growing global burden of Alzheimer’s disease, which is projected to affect over 100 million people worldwide by 2050. With increasing recognition of the role of inflammation in neurodegeneration, policy-makers and healthcare systems are looking toward innovative biologics that can delay disease progression and reduce long-term care costs.
Transaction Highlights
In the first animal cohort of this study, COYA 303 produced robust systemic and CNS immunomodulatory effects in the LPS-induced model of inflammation. Treatment with COYA 303 significantly enhanced Treg numbers and suppressive function, while also reducing peripheral activated myeloid cells. Importantly, the therapy attenuated neuroinflammation in both the cortex and hippocampus, regions critical to memory and cognition. The dual mechanism of combining LD-IL-2 with GLP-1RA confirmed earlier in vitro findings, showing synergistic benefits in enhancing Treg activity and dampening pro-inflammatory pathways. Experimental Cohorts 2 and 3 are currently underway to further assess the impact of treatment timing relative to the onset of inflammation, and the full dataset is expected to be presented or published in a peer-reviewed scientific forum.
Source: Coya Therapeutics, Inc. Press Release
